

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Review Proposal Project

**NICE Technology Appraisal No.375; Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed**

### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• AbbVie (adalimumab)</li> <li>• Amgen (adalimumab biosimilar)</li> <li>• Biogen (adalimumab biosimilar, etanercept biosimilar, infliximab biosimilar)</li> <li>• Bristol–Myers Squibb (abatacept)</li> <li>• Generics UK T/A Mylan (adalimumab biosimilar)</li> <li>• Hospira UK (infliximab biosimilar)</li> <li>• MSD (infliximab, golimumab)</li> <li>• Napp Pharmaceuticals (infliximab biosimilar)</li> <li>• Pfizer (etanercept, infliximab biosimilar)</li> <li>• Roche (tocilizumab)</li> <li>• Sandoz (adalimumab biosimilar, etanercept biosimilar)</li> <li>• UCB (certolizumab pegol)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Arthritis Action</li> <li>• Arthritis and Musculoskeletal Alliance</li> <li>• Muslim Council of Britain</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• National Rheumatoid Arthritis Society</li> <li>• Pain Concern</li> <li>• Pain Relief Foundation</li> <li>• Pain UK</li> <li>• Versus Arthritis</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• British Institute of Musculoskeletal Medicine</li> </ul>	<p><u>General commentators</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparators</u></p> <ul style="list-style-type: none"> <li>• Advanz Pharma (methotrexate)</li> <li>• Aspire Pharma Ltd (leflunomide)</li> <li>• Bristol Laboratories Ltd (hydroxychloroquine sulfate)</li> <li>• Eli Lilly (baricitinib)</li> <li>• Generics UK T/A Mylan (leflunomide)</li> <li>• Genzyme Therapeutics (sarilumab)</li> <li>• Hameln (methotrexate)</li> <li>• Hospira UK (methotrexate)</li> <li>• Medac (methotrexate, leflunomide)</li> <li>• Nordic Pharma Limited (methotrexate)</li> <li>• Orion (methotrexate)</li> <li>• Pfizer (methotrexate, sulfasalazine, tofacitinib)</li> </ul>

NICE Technology Appraisal No.375; Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Issue date: March 2019.

<ul style="list-style-type: none"> <li>• British Orthopaedic Association</li> <li>• British Geriatrics Society</li> <li>• British Society for Rheumatology</li> <li>• British Society of Rehabilitation Medicine</li> <li>• Primary Care Rheumatology Society</li> <li>• Rheumatoid Arthritis Surgical Society</li> <li>• Physiotherapy Pain Association</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• Welsh Government</li> <li>• NHS Basildon and Brentwood CCG</li> <li>• NHS Corby CCG</li> </ul>	<ul style="list-style-type: none"> <li>• Rosemont (methotrexate, sulfasalazine)</li> <li>• Sandoz (methotrexate, leflunomide)</li> <li>• Sanofi (leflunomide)</li> <li>• Therakind Limited (methotrexate)</li> <li>• Zentiva (hydroxychloroquine sulfate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Chronic Pain Policy Coalition</li> <li>• Cochrane Musculoskeletal Group</li> <li>• Genomics England</li> <li>• Orthopaedic Research UK</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>
--	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

**PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS**

## Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

## Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.